Major bleeding events
Showing 1 - 25 of >10,000
MACCE According to Time Interval of Taking Medication in Acute
Completed
- Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
- Esomezol Cap
-
Seoul, Korea, Republic ofHanmi Pharmaceutical Company Limited
Aug 2, 2022
Thromboembolic Events in Patients Receiving Kcentra® or Plasma
Completed
- Hemorrhage
- Kcentra®
- Plasma
-
Oakland, CaliforniaStudy Site
May 24, 2021
"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in
Not yet recruiting
- Patients With Atrial Fibrillation Receiving Oral Anticoagulants
- (no location specified)
Jul 27, 2023
Venous Thromboembolism and Bleeding Events inPopulation of Obese
Not yet recruiting
- Venous Thromboembolism
- (no location specified)
Apr 6, 2023
Troponin to Detect Major Cardiovasculaire Advserse Events on
Recruiting
- Cancer
- +2 more
- No intervention
-
Paris, FranceInstitut Mutualiste Montsouris
Aug 22, 2023
Noncardiac Surgery Trial in Guangzhou (Perioperative cardiac biomarker measurement)
Recruiting
- Noncardiac Surgery
- Perioperative cardiac biomarker measurement
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Apr 2, 2023
Anticoagulant Drug Intervention on Postoperative MALE and MACE
Recruiting
- Anticoagulant Drugs
- +2 more
- anticoagulant or antiplatelet drugs
-
Hangzhou, None Selected, ChinaFirst Affiliated Hospital of Zhejiang University
May 8, 2023
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Bleeding Disorder Trial in Charlottesville (Recombinant von Willebrand Factor)
Not yet recruiting
- Bleeding Disorder
- Recombinant von Willebrand Factor
-
Charlottesville, VirginiaUVA Hospital
Nov 3, 2023
Health Care Interventions and Outcomes of Major Bleedings in
Not yet recruiting
- Major Bleeding
- None (Observational study)
- (no location specified)
Nov 17, 2023
Diabetes, Type 2, Major Adverse Cardiac Events Trial in Hangzhou (CGM)
Not yet recruiting
- Diabetes Mellitus, Type 2
- Major Adverse Cardiac Events
- CGM
-
Hangzhou, Chinathe Second Affiliated Hospital Zhejiang University Schoolof Medi
Sep 23, 2023
Major Adverse Cardiovascular Events in Coronary Artery Disease
Completed
- Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
-
Jinan, Shandong, ChinaYuguo Chen
Sep 20, 2022
Obesity Trial (Naltrexone-Bupropion (NB) Combination, Placebo)
Not yet recruiting
- Obesity
- Naltrexone-Bupropion (NB) Combination
- Placebo
- (no location specified)
Oct 18, 2023
Basal Plasma Lithium Levels and Suicidal Events
Recruiting
- Major Depressive Disorder
- +2 more
- Blood sample
-
Montpellier, FranceCHU Montpellier
Dec 23, 2022
Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke Trial (low-dose rivaroxaban, Standard-dose rivaroxaban)
Not yet recruiting
- Atrial Fibrillation
- +3 more
- low-dose rivaroxaban
- Standard-dose rivaroxaban
- (no location specified)
Oct 25, 2023
COVID-19, Thrombosis Embolism, Bleeding Trial in Stockholm (Dexamethasone)
Completed
- COVID-19
- +2 more
-
Stockholm, Stockholms Län, SwedenSödersjukhuset
Jun 24, 2022
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
Adverse Events in Acute Limb Ischemic Patient Undergoing
Recruiting
- Major Adverse Cardiac Events
- Adverse Effect of Unspecified General Anesthetic
-
Bangkok, Thailand
- +1 more
May 3, 2022
Acute Kidney Injury, Septic Shock, Nicotinamide Trial in Amiens (Nicotinamide treatment, treatment)
Recruiting
- Acute Kidney Injury
- +3 more
- Nicotinamide treatment
- placebo treatment
-
Amiens, FranceCHU Amiens
Dec 8, 2022
Ventilator Lung, Liver Cirrhosis, Hepatocellular Carcinoma Trial in Seoul (conventional tidal volume (tidal volume [ml]= ideal
Not yet recruiting
- Ventilator Lung
- +3 more
- conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group
- low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume
-
Seoul, Korea, Republic ofSeoul National University Hospital
Aug 3, 2022
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
Coronary Artery Disease Trial in United States (Colchicine, Placebo)
Not yet recruiting
- Coronary Artery Disease
- Colchicine
- Placebo
-
Long Beach, California
- +4 more
Nov 15, 2022
Venous Thromboembolism, Anticoagulant-induced Bleeding, Venous Thromboses Trial in Metepec (Rivaroxaban 20 MG [Xarelto], Aspirin
Completed
- Venous Thromboembolism
- +3 more
- Rivaroxaban 20 MG [Xarelto]
- +2 more
-
Metepec, Estado De Mexico, MexicoInstituto Mexicano Del Seguro Social
Aug 24, 2022
Cardiovascular Primary Prevention Strategy Trial in Murray (Coronary Artery Calcium Screening and Statin Treatment, Standard
Recruiting
- Cardiovascular Primary Prevention Strategy
- Coronary Artery Calcium Screening and Statin Treatment
- Standard Treatment
-
Murray, UtahIntermountain Medical Center and Intermountain Clinics
Aug 8, 2022